- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Gensight Biologics SA (SIGHT)
Gensight Biologics SA stock price live, this page displays EPA SIGHT stock exchange data. View the SIGHT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Gensight Biologics SA real time stock price chart below.
What Is the Gensight Biologics SA Stock Price Today?
The Gensight Biologics SA stock price today is 0.16.
What Is the Stock Symbol for Gensight Biologics SA?
The stock symbol for Gensight Biologics SA is ""SIGHT.""
What Stock Exchange Does Gensight Biologics SA Trade On?
Gensight Biologics SA is listed and trades on the Paris stock exchange.
Is Gensight Biologics SA a Good Stock to Buy?
Determining whether Gensight Biologics SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SIGHT quote. (ISIN: FR0013183985)
What Is the Gensight Biologics SA Stock Price Today?
The Gensight Biologics SA stock price today is 0.16.
What Is the Stock Symbol for Gensight Biologics SA?
The stock symbol for Gensight Biologics SA is ""SIGHT.""
What Stock Exchange Does Gensight Biologics SA Trade On?
Gensight Biologics SA is listed and trades on the Paris stock exchange.
Is Gensight Biologics SA a Good Stock to Buy?
Determining whether Gensight Biologics SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SIGHT quote. (ISIN: FR0013183985)
Paris
Currency in EUR
0.16
0.00(0.00%)
Closed·
Fair Value
An estimate of a Gensight Biologics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.16
0.16
52 wk Range
0.12
0.49
SIGHT Scorecard
Full Analysis
Operates with a significant debt burden
SIGHT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Gensight Biologics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.160.16
52 wk Range
0.120.49
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SIGHT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Gensight Biologics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
0.46
Upside
+187.50%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Strong Buy
Gensight Biologics SA Company Profile
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa and dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. It has license agreements with Sorbonne Université, CNRS, Inserm and SATT Lutech; Inserm Transfert S.A, Genethon, and Harvard; Massachusetts Institute of Technology; Novartis Pharma AG; Sorbonne University, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale and Satt Lutech; Association Française contre les Myopathies, Inserm Transfert S.A; and non-exclusive license agreement with Adverum Biotechnologies. The company was incorporated in 2012 and is headquartered in Paris, France.
Compare SIGHT to Peers and Sector
Metrics to compare | SIGHT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSIGHTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.7x | −3.2x | −0.6x | |
PEG Ratio | −0.02 | 0.05 | 0.00 | |
Price/Book | −0.9x | 1.5x | 2.6x | |
Price / LTM Sales | 9.3x | 3.9x | 3.3x | |
Upside (Analyst Target) | 187.5% | 130.5% | 38.7% | |
Fair Value Upside | Unlock | 15.6% | 5.1% | Unlock |
Analyst Ratings
1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 0.46
(+187.50% Upside)
Earnings
Latest Release
Apr 07, 2025
EPS / Forecast
-0.07 / --
Revenue / Forecast
897.00K / --
People Also Watch
FAQ
What Stock Exchange Does Gensight Biologics Trade On?
Gensight Biologics is listed and trades on the Paris Stock Exchange stock exchange.
What Is the Stock Symbol for Gensight Biologics?
The stock symbol for Gensight Biologics is "SIGHT."
What Is the Gensight Biologics Market Cap?
As of today, Gensight Biologics market cap is 24.36M.
What Is Gensight Biologics's Earnings Per Share (TTM)?
The Gensight Biologics EPS (TTM) is -0.15.
When Is the Next Gensight Biologics Earnings Date?
Gensight Biologics will release its next earnings report on 18 Sept 2025.
From a Technical Analysis Perspective, Is SIGHT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Gensight Biologics Stock Split?
Gensight Biologics has split 0 times.
How Many Employees Does Gensight Biologics Have?
Gensight Biologics has 16 employees.
What is the current trading status of Gensight Biologics (SIGHT)?
As of 28 Aug 2025, Gensight Biologics (SIGHT) is trading at a price of 0.16, with a previous close of 0.16. The stock has fluctuated within a day range of 0.16 to 0.16, while its 52-week range spans from 0.12 to 0.49.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.